Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03828084 · ClinicalTrials.gov registry record · Phase 1
Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects
A Phase 1 study, sponsored by EpiDestiny.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03828084: Completed Phase 1 study, sponsored by EpiDestiny.
NCT03828084 is a Phase 1 study that has completed, run by EpiDestiny. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03828084, a Phase 1 study, has completed, sponsored by EpiDestiny.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
To study the pharmacokinetic profiles of decitabine and tetrahydrouridine (THU) from 3 modified release formulations in healthy subjects.
Interventions
- DRUG Decitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2019-04-03 |
| Est. Completion | 2019-05-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03828084
The ClinicalTrials.gov registry entry for NCT03828084 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EpiDestiny, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Decitabine is the first listed.
NCT03828084 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03828084 about?
NCT03828084 is a clinical study titled "Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects". To study the pharmacokinetic profiles of decitabine and tetrahydrouridine (THU) from 3 modified release formulations in healthy subjects.
What is the current status of trial NCT03828084?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2019-04-03. Estimated completion is 2019-05-03.
What interventions are being tested in trial NCT03828084?
The interventions under investigation include: Decitabine (DRUG).
Who is sponsoring clinical trial NCT03828084?
This trial is sponsored by EpiDestiny, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.